Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Equity Ratio (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Equity Ratio readings, the most recent being 0.87 for Q4 2025.

  • Quarterly Equity Ratio fell 8.15% to 0.87 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.87 through Dec 2025, down 8.15% year-over-year, with the annual reading at 0.87 for FY2025, 8.15% down from the prior year.
  • Equity Ratio hit 0.87 in Q4 2025 for Oramed Pharmaceuticals, down from 0.92 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.96 in Q2 2023 and bottomed at 0.64 in Q3 2023.
  • Average Equity Ratio over 5 years is 0.89, with a median of 0.93 recorded in 2021.
  • The largest annual shift saw Equity Ratio soared 48.92% in 2021 before it plummeted 31.07% in 2023.
  • Oramed Pharmaceuticals' Equity Ratio stood at 0.93 in 2021, then increased by 0.27% to 0.94 in 2022, then decreased by 21.02% to 0.74 in 2023, then grew by 27.54% to 0.94 in 2024, then decreased by 8.15% to 0.87 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Equity Ratio are 0.87 (Q4 2025), 0.92 (Q3 2025), and 0.95 (Q2 2025).